Preoperative Cisplatin in Early Stage Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

Cisplatin

Intravenously once every three weeks for a total of 12 weeks

Trial Locations (3)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Breast Cancer Research Foundation

OTHER

lead

Dana-Farber Cancer Institute

OTHER